Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines

Lindsay Kim, Brian Rha, Jon S. Abramson, Larry J. Anderson, Carrie L. Byington, Grace L. Chen, John Devincenzo, Kathryn M. Edwards, Janet A. Englund, Ann R. Falsey, Marie R. Griffin, Ruth A. Karron, Karen G. Martin, H. Cody Meissner, Flor M. Munoz, Andrew T. Pavia, Pedro A. Piedra, William Schaffner, Eric A.F. Simões, Rosalyn Singleton & 4 others H. Keipp Talbot, Edward E. Walsh, Jane R. Zucker, Susan I. Gerber

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently. No effective antivirals or vaccines for RSV are approved for use in the United States; however, there are at least 50 vaccines and monoclonal antibody products in development, with those targeting older adults and pregnant women (to protect young infants) in phase 2 and 3 clinical trials. Unanswered questions regarding RSV epidemiology need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of impact and future recommendations. The Centers for Disease Control and Prevention (CDC) convened a technical consultation to gather input from external subject matter experts on their individual perspectives regarding evidence gaps in current RSV epidemiology in the United States, potential studies and surveillance platforms needed to fill these gaps, and prioritizing efforts. Participants articulated their individual views, and CDC staff synthesized individuals' input into this report.

Original languageEnglish (US)
Pages (from-to)1020-1025
Number of pages6
JournalClinical Infectious Diseases
Volume65
Issue number6
DOIs
StatePublished - Sep 15 2017

Fingerprint

Respiratory Syncytial Viruses
Virus Diseases
Respiratory Syncytial Virus Vaccines
Epidemiology
Vaccines
Centers for Disease Control and Prevention (U.S.)
Phase III Clinical Trials
Respiratory System
Antiviral Agents
Pregnant Women
Referral and Consultation
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Kim, L., Rha, B., Abramson, J. S., Anderson, L. J., Byington, C. L., Chen, G. L., ... Gerber, S. I. (2017). Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines. Clinical Infectious Diseases, 65(6), 1020-1025. https://doi.org/10.1093/cid/cix432

Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines. / Kim, Lindsay; Rha, Brian; Abramson, Jon S.; Anderson, Larry J.; Byington, Carrie L.; Chen, Grace L.; Devincenzo, John; Edwards, Kathryn M.; Englund, Janet A.; Falsey, Ann R.; Griffin, Marie R.; Karron, Ruth A.; Martin, Karen G.; Meissner, H. Cody; Munoz, Flor M.; Pavia, Andrew T.; Piedra, Pedro A.; Schaffner, William; Simões, Eric A.F.; Singleton, Rosalyn; Talbot, H. Keipp; Walsh, Edward E.; Zucker, Jane R.; Gerber, Susan I.

In: Clinical Infectious Diseases, Vol. 65, No. 6, 15.09.2017, p. 1020-1025.

Research output: Contribution to journalArticle

Kim, L, Rha, B, Abramson, JS, Anderson, LJ, Byington, CL, Chen, GL, Devincenzo, J, Edwards, KM, Englund, JA, Falsey, AR, Griffin, MR, Karron, RA, Martin, KG, Meissner, HC, Munoz, FM, Pavia, AT, Piedra, PA, Schaffner, W, Simões, EAF, Singleton, R, Talbot, HK, Walsh, EE, Zucker, JR & Gerber, SI 2017, 'Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines', Clinical Infectious Diseases, vol. 65, no. 6, pp. 1020-1025. https://doi.org/10.1093/cid/cix432
Kim, Lindsay ; Rha, Brian ; Abramson, Jon S. ; Anderson, Larry J. ; Byington, Carrie L. ; Chen, Grace L. ; Devincenzo, John ; Edwards, Kathryn M. ; Englund, Janet A. ; Falsey, Ann R. ; Griffin, Marie R. ; Karron, Ruth A. ; Martin, Karen G. ; Meissner, H. Cody ; Munoz, Flor M. ; Pavia, Andrew T. ; Piedra, Pedro A. ; Schaffner, William ; Simões, Eric A.F. ; Singleton, Rosalyn ; Talbot, H. Keipp ; Walsh, Edward E. ; Zucker, Jane R. ; Gerber, Susan I. / Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines. In: Clinical Infectious Diseases. 2017 ; Vol. 65, No. 6. pp. 1020-1025.
@article{a4c2e192c59c49e9ba689575a2fbc4ba,
title = "Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines",
abstract = "Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently. No effective antivirals or vaccines for RSV are approved for use in the United States; however, there are at least 50 vaccines and monoclonal antibody products in development, with those targeting older adults and pregnant women (to protect young infants) in phase 2 and 3 clinical trials. Unanswered questions regarding RSV epidemiology need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of impact and future recommendations. The Centers for Disease Control and Prevention (CDC) convened a technical consultation to gather input from external subject matter experts on their individual perspectives regarding evidence gaps in current RSV epidemiology in the United States, potential studies and surveillance platforms needed to fill these gaps, and prioritizing efforts. Participants articulated their individual views, and CDC staff synthesized individuals' input into this report.",
author = "Lindsay Kim and Brian Rha and Abramson, {Jon S.} and Anderson, {Larry J.} and Byington, {Carrie L.} and Chen, {Grace L.} and John Devincenzo and Edwards, {Kathryn M.} and Englund, {Janet A.} and Falsey, {Ann R.} and Griffin, {Marie R.} and Karron, {Ruth A.} and Martin, {Karen G.} and Meissner, {H. Cody} and Munoz, {Flor M.} and Pavia, {Andrew T.} and Piedra, {Pedro A.} and William Schaffner and Sim{\~o}es, {Eric A.F.} and Rosalyn Singleton and Talbot, {H. Keipp} and Walsh, {Edward E.} and Zucker, {Jane R.} and Gerber, {Susan I.}",
year = "2017",
month = "9",
day = "15",
doi = "10.1093/cid/cix432",
language = "English (US)",
volume = "65",
pages = "1020--1025",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines

AU - Kim, Lindsay

AU - Rha, Brian

AU - Abramson, Jon S.

AU - Anderson, Larry J.

AU - Byington, Carrie L.

AU - Chen, Grace L.

AU - Devincenzo, John

AU - Edwards, Kathryn M.

AU - Englund, Janet A.

AU - Falsey, Ann R.

AU - Griffin, Marie R.

AU - Karron, Ruth A.

AU - Martin, Karen G.

AU - Meissner, H. Cody

AU - Munoz, Flor M.

AU - Pavia, Andrew T.

AU - Piedra, Pedro A.

AU - Schaffner, William

AU - Simões, Eric A.F.

AU - Singleton, Rosalyn

AU - Talbot, H. Keipp

AU - Walsh, Edward E.

AU - Zucker, Jane R.

AU - Gerber, Susan I.

PY - 2017/9/15

Y1 - 2017/9/15

N2 - Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently. No effective antivirals or vaccines for RSV are approved for use in the United States; however, there are at least 50 vaccines and monoclonal antibody products in development, with those targeting older adults and pregnant women (to protect young infants) in phase 2 and 3 clinical trials. Unanswered questions regarding RSV epidemiology need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of impact and future recommendations. The Centers for Disease Control and Prevention (CDC) convened a technical consultation to gather input from external subject matter experts on their individual perspectives regarding evidence gaps in current RSV epidemiology in the United States, potential studies and surveillance platforms needed to fill these gaps, and prioritizing efforts. Participants articulated their individual views, and CDC staff synthesized individuals' input into this report.

AB - Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently. No effective antivirals or vaccines for RSV are approved for use in the United States; however, there are at least 50 vaccines and monoclonal antibody products in development, with those targeting older adults and pregnant women (to protect young infants) in phase 2 and 3 clinical trials. Unanswered questions regarding RSV epidemiology need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of impact and future recommendations. The Centers for Disease Control and Prevention (CDC) convened a technical consultation to gather input from external subject matter experts on their individual perspectives regarding evidence gaps in current RSV epidemiology in the United States, potential studies and surveillance platforms needed to fill these gaps, and prioritizing efforts. Participants articulated their individual views, and CDC staff synthesized individuals' input into this report.

UR - http://www.scopus.com/inward/record.url?scp=85031911053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031911053&partnerID=8YFLogxK

U2 - 10.1093/cid/cix432

DO - 10.1093/cid/cix432

M3 - Article

VL - 65

SP - 1020

EP - 1025

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -